🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today, Acadia Pharmaceuticals and Saniona announced initial positive results from ACP-711 (formerly SAN711) Phase 1 Study. Read more here: bit.ly/41hDojc

Join us at the 46th National Conference on Pediatric Health organized by the NAPNAP where we will be presenting data on #RettSyndrome. Learn more and register here: bit.ly/4hSS6nT.

Today we announced that the journal Med published clinical data evaluating the safety and tolerability of our treatment option for girls aged two to four living with #RettSyndrome. Learn more: bit.ly/4bqMz5C.

Earlier this week, we engaged with both current shareholders and prospective investors at TD Cowen’s 45th Annual Health Care Conference. Tune in to our fireside chat to hear about the latest company updates we shared: bit.ly/3Dupqm4

We will be attending the PALTmed | Post-Acute & Long-Term Care Medical Assn annual conference where we look forward to connecting with professionals in the post-acute & long-term care sectors as we present data on our treatment for #ParkinsonsDisease. Learn more and register here: bit.ly/3DncPBc. #PALTC25

The American Association for Geriatric Psychiatry Annual Meeting kicks off tomorrow in Phoenix, AZ, and we’re looking forward to presenting our #AlzheimersDisease research. Learn more: bit.ly/3QTMdL6.

We’re looking forward to connecting with the medical genetics community from around the world at the 2025 ACMG Annual Clinical Genetics Meeting where we will be presenting our findings in #RettSyndrome. Learn more and register: bit.ly/3QNnRTo. #ACMGMtg25

We’re looking forward to participating at upcoming #investor conferences, including Stifel’s 2025 Virtual CNS Forum & the 24th Annual Needham Virtual Healthcare Conference. Learn about our participation: bit.ly/4hovR8o $ACAD

This weekend at the American Academy of Neurology 2025 Annual Meeting, we’ll be sharing our recent findings in #RettSyndrome and connecting with researchers in neuroscience from around the world. Learn more and register here: bit.ly/3JmHrQy. #AANAM

Today, we shared our Q1 2025 #earnings results. Read our $ACAD financial summary and key updates here: bit.ly/3Z4Plsa.

Tomorrow, we’re looking forward to participating in a fireside chat at the BofA Securities 2025 Health Care Conference. Learn more: bit.ly/4j2TX9o

We look forward to sharing our latest findings in #RettSyndrome and #PraderWilliSyndrome care during this year’s ISPOR annual meeting in Montreal, Canada. Learn more: bit.ly/4jUJrT1 #ISPOR2025

Today we announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia in patent litigation regarding the formulation for our Parkinson’s Disease Psychosis treatment. Read more here: bit.ly/4ktyasN

Today we announced that Allyson McMillan-Youngblood has been appointed to Senior Vice President, Rare Disease Franchise. Learn more: bit.ly/43DAYN6

We’re looking forward to participating in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th. Learn more: bit.ly/4myXijH.

Join Acadia's first-ever R&D Day. The leadership team, alongside KOLs and caregivers, will offer a deeper look into the newly disclosed programs, the development strategy and will showcase some of the promising innovation taking shape across the pipeline: bit.ly/3HGC0Al

We’re headed to Boston for the @RettSyndrome Scientific Meeting. We look forward to presenting our latest #RettSyndrome research & engaging in insightful discussions about the most urgent challenges surrounding the Rett syndrome community. Learn more: bit.ly/3FL8hWt.

Next week, we will be joining Canadian Neurological Sciences Federation and leading neuroscience professionals at the #2025CNSF Congress. We look forward to sharing our recent findings in #RettSyndrome with experts in neurology, pediatric neurology, and neuroscience. Learn more: bit.ly/3FsqcBj

Today, we announced that the U.S. Court of Appeals for the Federal Circuit affirmed the prior Delaware district court ruling in favor of our Parkinson's Disease Psychosis treatment's composition of matter patent. Read more: bit.ly/4mQX6fw

We’re looking forward to connecting with the neurology community this weekend at the 11th Congress of the European Academy of Neurology in Helsinki, Finland. Learn more and register here: bit.ly/4dKDuFG. #EAN2025